Clinical trials
Terminated Barrett Esophagus trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 30 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mayo Clinic | 5 |
| Midwest Biomedical Research | 4 |
| CSA Medical, Inc. | 2 |
| Washington University School of Medicine | 2 |
| Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 1 |
| Anandasabapathy, Sharmila, M.D. | 1 |
| CDx Diagnostics | 1 |
| Columbia University | 1 |
| DHR Health Institute for Research and Development | 1 |
| Erbe Elektromedizin GmbH | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Barrett Esophagus | 30 |
| Gastroesophageal Reflux | 11 |
| Esophageal Neoplasms | 5 |
| Heartburn | 2 |
| Carcinoma in Situ | 1 |
| Celiac Disease | 1 |
| Cholelithiasis | 1 |
| Colitis, Lymphocytic | 1 |
| Colitis, Microscopic | 1 |
| Colitis, Ulcerative | 1 |
Trials
Showing 76 to 30 of 30. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.